Search Results - "LAMBORN, Kathleen"

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group by WEN, Patrick Y, MACDONALD, David R, TSIEN, Christina, MIKKELSEN, Tom, WONG, Eric T, CHAMBERLAIN, Marc C, STUPP, Roger, LAMBORN, Kathleen R, VOGELBAUM, Michael A, VAN DEN BENT, Martin J, CHANG, Susan M, REARDON, David A, CLOUGHESY, Timothy F, SORENSEN, A. Gregory, GALANIS, Evanthia, DEGROOT, John, WICK, Wolfgang, GILBERT, Mark R, LASSMAN, Andrew B

“…Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed…”
Get full text

Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas by SMITH, Justin S, CHANG, Edward F, LAMBORN, Kathleen R, CHANG, Susan M, PRADOS, Michael D, CHA, Soonmee, TIHAN, Tarik, VANDENBERG, Scott, MCDERMOTT, Michael W, BERGER, Mitchel S

“…The prognostic role of extent of resection (EOR) of low-grade gliomas (LGGs) is a major controversy. We designed a retrospective study to assess the influence…”
Get full text

The superiority of conservative resection and adjuvant radiation for craniopharyngiomas by Schoenfeld, Adam, Pekmezci, Melike, Barnes, Michael J., Tihan, Tarik, Gupta, Nalin, Lamborn, Kathleen R., Banerjee, Anu, Mueller, Sabine, Chang, Susan, Berger, Mitchel S., Haas-Kogan, Daphne

“…The purpose of this study is to evaluate the roles of resection extent and adjuvant radiation in the treatment of craniopharyngiomas. We reviewed the records…”
Get full text

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group by Lin, Nancy U, Dr, Lee, Eudocia Q, MD, Aoyama, Hidefumi, Prof, Barani, Igor J, MD, Baumert, Brigitta G, Prof, Brown, Paul D, Prof, Camidge, D Ross, MD, Chang, Susan M, Prof, Dancey, Janet, Prof, Gaspar, Laurie E, Prof, Harris, Gordon J, Prof, Hodi, F Stephen, MD, Kalkanis, Steven N, MD, Lamborn, Kathleen R, Prof, Linskey, Mark E, Prof, Macdonald, David R, MD, Margolin, Kim, Prof, Mehta, Minesh P, MD, Schiff, David, Prof, Soffietti, Riccardo, Prof, Suh, John H, Prof, van den Bent, Martin J, Prof, Vogelbaum, Michael A, Prof, Wefel, Jeffrey S, PhD, Wen, Patrick Y, Prof

“…Summary Therapeutic outcomes for patients with brain metastases need to improve. A critical review of trials specifically addressing brain metastases shows key…”
Get full text

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study by DE GROOT, John F, LAMBORN, Kathleen R, MEHTA, Minesh P, LASSMAN, Andrew B, DEANGELIS, Lisa M, YUNG, W. K. Alfred, CHEN, Alice, PRADOS, Michael D, WEN, Patrick Y, CHANG, Susan M, GILBERT, Mark R, CLOUGHESY, Timothy F, ALDAPE, Kenneth, JUN YAO, JACKSON, Edward F, LIEBERMAN, Frank, ROBINS, H. Ian

“…Antivascular endothelial growth factor (anti-VEGF) therapy is a promising treatment approach for patients with recurrent glioblastoma. This single-arm phase II…”
Get full text

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors by Vivanco, Igor, Robins, H Ian, Rohle, Daniel, Campos, Carl, Grommes, Christian, Nghiemphu, Phioanh Leia, Kubek, Sara, Oldrini, Barbara, Chheda, Milan G, Yannuzzi, Nicolas, Tao, Hui, Zhu, Shaojun, Iwanami, Akio, Kuga, Daisuke, Dang, Julie, Pedraza, Alicia, Brennan, Cameron W, Heguy, Adriana, Liau, Linda M, Lieberman, Frank, Yung, W K Alfred, Gilbert, Mark R, Reardon, David A, Drappatz, Jan, Wen, Patrick Y, Lamborn, Kathleen R, Chang, Susan M, Prados, Michael D, Fine, Howard A, Horvath, Steve, Wu, Nian, Lassman, Andrew B, DeAngelis, Lisa M, Yong, William H, Kuhn, John G, Mischel, Paul S, Mehta, Minesh P, Cloughesy, Timothy F, Mellinghoff, Ingo K

“…Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions in the extracellular (EC) domain. Unlike…”
Get more information

Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma by PRADOS, Michael D, CHANG, Susan M, FEDOROFF, Anne, SNEED, Penny K, BERGER, Mitchel S, MCDERMOTT, Michael W, PARSA, Andrew T, VANDENBERG, Scott, JAMES, C. David, LAMBORN, Kathleen R, STOKOE, David, HAAS-KOGAN, Daphne A, BUTOWSKI, Nicholas, DEBOER, Rebecca, PARVATANENI, Rupa, CARLINER, Hannah, KABUUBI, Paul, AYERS-RINGLER, Jennifer, RABBITT, Jane, PAGE, Margaretta

“…This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme…”
Get full text

Seizure characteristics and control following resection in 332 patients with low-grade gliomas by CHANG, Edward F, POTTS, Matthew B, EVREN KELES, G, LAMBORN, Kathleen R, CHANG, Susan M, BARBARO, Nicholas M, BERGER, Mitchel S

“…Seizures play an important role in the clinical presentation and postoperative quality of life of patients who undergo surgical resection of low-grade gliomas…”
Get full text

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas by Lamborn, Kathleen R, Yung, W K Alfred, Chang, Susan M, Wen, Patrick Y, Cloughesy, Timothy F, DeAngelis, Lisa M, Robins, H Ian, Lieberman, Frank S, Fine, Howard A, Fink, Karen L, Junck, Larry, Abrey, Lauren, Gilbert, Mark R, Mehta, Minesh, Kuhn, John G, Aldape, Kenneth D, Hibberts, Janelle, Peterson, Pamela M, Prados, Michael D

“…The North American Brain Tumor Consortium (NABTC) uses 6-month progression-free survival (6moPFS) as the efficacy end point of therapy trials for adult…”
Get full text

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib by Haas-Kogan, Daphne A., Prados, Michael D., Tihan, Tarik, Eberhard, David A., Jelluma, Nannette, Arvold, Nils D., Baumber, Rachel, Lamborn, Kathleen R., Kapadia, Ami, Malec, Mary, Berger, Mitchel S., Stokoe, David

“…Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (also known as Tarceva or OSI-774) has shown promising response…”
Get full text

Prognostic Factors for Survival in Patients Treated With Stereotactic Radiosurgery for Recurrent Brain Metastases After Prior Whole Brain Radiotherapy by Caballero, Jorge A., M.D, Sneed, Penny K., M.D, Lamborn, Kathleen R., Ph.D, Ma, Lijun, Ph.D, Denduluri, Sandeep, M.D, Nakamura, Jean L., M.D, Barani, Igor J., M.D, McDermott, Michael W., M.D

“…Purpose To evaluate prognostic factors for survival after stereotactic radiosurgery (SRS) for new, progressive, or recurrent brain metastases (BM) after prior…”
Get full text

Preoperative prognostic classification system for hemispheric low-grade gliomas in adults by Chang, Edward F, Smith, Justin S, Chang, Susan M, Lamborn, Kathleen R, Prados, Michael D, Butowski, Nicholas, Barbaro, Nicholas M, Parsa, Andrew T, Berger, Mitchel S, McDermott, Michael M

“…Hemispheric low-grade gliomas (LGGs) have an unpredictable progression and overall survival (OS) profile. As a result, the objective in the present study was…”
Get full text

Preoperative prognostic classification system for hemispheric low-grade gliomas in adults : Clinical article by CHANG, Edward F, SMITH, Justin S, CHANG, Susan M, LAMBORN, Kathleen R, PRADOS, Michael D, BUTOWSKI, Nicholas, BARBARO, Nicholas M, PARSA, Andrew T, BERGER, Mitchel S, MCDERMOTT, Michael M

“…Object Hemispheric low-grade gliomas (LGGs) have an unpredictable progression and overall survival (OS) profile. As a result, the objective in the present…”
Get full text

Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas by CHANG, Edward F, ZADA, Gabriel, KIM, Sang, LAMBORN, Kathleen R, QUINONES-HINOJOSA, Alfredo, BLAKE TYRRELL, J, WILSON, Charles B, KUNWAR, Sandeep

“…Long-term outcomes following surgery for nonfunctional pituitary adenomas (NFPAs) are unclear. The role of adjuvant radiation therapy is therefore…”
Get full text

A multicenter, prospective pilot study of gamma knife radiosurgery for mesial temporal lobe epilepsy: Seizure response, adverse events, and verbal memory by Barbaro, Nicholas M., Quigg, Mark, Broshek, Donna K., Ward, Mariann M., Lamborn, Kathleen R., Laxer, Kenneth D., Larson, David A., Dillon, William, Verhey, Lynn, Garcia, Paul, Steiner, Ladislau, Heck, Christine, Kondziolka, Douglas, Beach, Robert, Olivero, William, Witt, Thomas C., Salanova, Vicenta, Goodman, Robert

“…Objective The safety, efficacy, and morbidity of radiosurgery (RS) must be established before it can be offered as an alternative to open surgery for…”
Get full text

Gene Expression Profiling Reveals Molecularly and Clinically Distinct Subtypes of Glioblastoma Multiforme by Liang, Yu, Diehn, Maximilian, Watson, Nathan, Bollen, Andrew W., Aldape, Ken D., Nicholas, M. Kelly, Lamborn, Kathleen R., Berger, Mitchel S., Botstein, David, Brown, Patrick O., Israel, Mark A., Cavenee, Webster K.

“…Glioblastoma multiforme (GBM) is the most common form of malignant glioma, characterized by genetic instability, intratumoral histopathological variability,…”
Get full text

Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 by Wen, Patrick Y, Yung, W K Alfred, Lamborn, Kathleen R, Dahia, Patricia L, Wang, Yanfeng, Peng, Bin, Abrey, Lauren E, Raizer, Jeffrey, Cloughesy, Timothy F, Fink, Karen, Gilbert, Mark, Chang, Susan, Junck, Larry, Schiff, David, Lieberman, Frank, Fine, Howard A, Mehta, Minesh, Robins, H Ian, DeAngelis, Lisa M, Groves, Morris D, Puduvalli, Vinay K, Levin, Victor, Conrad, Charles, Maher, Elizabeth A, Aldape, Kenneth, Hayes, Michael, Letvak, Laurie, Egorin, Merrill J, Capdeville, Renaud, Kaplan, Richard, Murgo, Anthony J, Stiles, Charles, Prados, Michael D

“…Purpose: Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas…”
Get full text

Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study by Lim, Daniel A., Tarapore, Phiroz, Chang, Edward, Burt, Marlene, Chakalian, Lenna, Barbaro, Nicholas, Chang, Susan, Lamborn, Kathleen R., McDermott, Michael W.

“…Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures. PHT, however, has many undesirable side…”
Get full text

Conditional Probability of Survival in Patients With Newly Diagnosed Glioblastoma by POLLEY, Mei-Yin C, LAMBORN, Kathleen R, CHANG, Susan M, BUTOWSKI, Nicholas, CLARKE, Jennifer L, PRADOS, Michael

“…The disease outcome for patients with cancer is typically described in terms of estimated survival from diagnosis. Conditional probability offers more relevant…”
Get full text

Suprasellar Rathke Cleft Cysts; Clinical Presentation and Treatment Outcomes by Potts, Matthew B., Jahangiri, Arman, Lamborn, Kathleen R., Blevins, Lewis S., Kunwar, Sandeep, Aghi, Manish K.

“…Abstract BACKGROUND Rathke cleft cysts (RCCs), benign remnants of the Rathke pouch typically arising in the sella, sometimes have suprasellar extension. Purely…”
Get full text